What Is Afamelanotide?
Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide in the body. It works by activating melanocortin receptors, which stimulate melanin production in the skin. The FDA approved afamelanotide in 2014 specifically for reducing phototoxic reactions in adult patients with erythropoietic protoporphyria (EPP).
EPP is a rare inherited metabolic disorder caused by deficiency in the enzyme ferrochelatase, leading to accumulation of protoporphyrin in red blood cells and skin. Patients with EPP experience severe, sometimes disabling pain, burning, and blistering when exposed to sunlight. Afamelanotide addresses this by increasing melanin in the epidermis, which acts as a natural UV filter.
Clinical Evidence for Afamelanotide
A landmark phase 3 trial published in The Lancet in 2014 demonstrated that afamelanotide combined with sun protection significantly reduced phototoxic reactions compared to sun protection alone. The study involved 74 patients with EPP and showed a 73% reduction in the number of days with phototoxic reactions over 6 months of treatment.
With 23 clinical trials on record, afamelanotide has been extensively studied in EPP populations. The compound is authorised in the European Union under the brand name Scenesse and available in the US via the FDA.
How Afamelanotide Is Administered
Afamelanotide is delivered as a subcutaneous implant—a small biodegradable rod placed under the skin. Each implant typically lasts about 60 days and releases the peptide gradually into the bloodstream, maintaining steady hormone levels without daily injections.
What Is Triptorelin?
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist, a peptide that mimics the natural GnRH released by the hypothalamus. When administered, it initially stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), but with continued use, it desensitizes the pituitary and suppresses the release of these hormones. This leads to dramatic reductions in testosterone (in men) and estrogen (in women).
The FDA has approved triptorelin for prostate cancer, endometriosis, and central precocious puberty—conditions where reducing sex hormone production is therapeutically beneficial.
Clinical Evidence for Triptorelin
Triptorelin has the strongest evidence base of the two compounds, with 40 clinical trials documented. A large phase 3 trial in advanced prostate cancer showed that triptorelin achieved castrate levels of testosterone (< 0.5 ng/mL) in 99% of men and maintained suppression throughout treatment.
In endometriosis, research indicates that GnRH agonists like triptorelin reduce pain and lesion burden by creating a hypo-estrogenic state. For central precocious puberty (CPP), triptorelin slows bone age advancement and allows children to reach near-normal adult height.
How Triptorelin Is Administered
Triptorelin is available as:
- Monthly intramuscular injections (3.75 mg or 4 mg)
- 3-month depot formulations (11.25 mg)
- 6-month depot formulations (22.5 mg)
Depot formulations use microsphere technology to release the peptide slowly over weeks or months, reducing injection frequency.
Key Differences at a Glance
| Feature | Afamelanotide | Triptorelin | |---------|---------------|-------------| | Mechanism | Melanocortin agonist (stimulates melanin) | GnRH agonist (suppresses sex hormones) | | Primary use | Erythropoietic protoporphyria (EPP) | Prostate cancer, endometriosis, CPP | | FDA status | Approved (2014) | Approved (multiple indications) | | EMA status | Authorised (Scenesse) | Not authorised | | Health Canada | Not approved | Approved | | Clinical trials | 23 | 40 | | Administration | Subcutaneous implant (~60 days) | IM injection (monthly or depot) | | Onset of action | Gradual (days to weeks) | Initial surge, then suppression (1-3 weeks) | | Disease specificity | Ultra-rare genetic disorder | Common cancers and endocrine disorders |
Mechanism: How They Work Differently
This is where afamelanotide and triptorelin diverge most sharply.
Afamelanotide acts on melanocortin receptors distributed throughout the skin and other tissues. By stimulating these receptors, it increases melanin synthesis—the body's natural photoprotective pigment. The effect is cosmetic and photoprotective but doesn't change systemic hormone levels. Research shows melanin absorbs and scatters UV radiation, providing an internal sunscreen effect.
Triptorelin works on the hypothalamic-pituitary-gonadal (HPG) axis. It's a peptide that binds to GnRH receptors on pituitary gonadotroph cells. Initially, this causes a surge in LH and FSH (called "flare"), but receptor desensitization leads to sustained suppression of these hormones and, downstream, dramatic reductions in testosterone or estrogen. This is a systemic endocrine intervention, not a topical or local effect.
Think of it this way: afamelanotide is a photoprotective cosmetic-biological intervention. Triptorelin is a systemic hormone-suppression therapy.
Regulatory Status and Availability
Afamelanotide
- FDA: Approved (2014) under the brand name Scenesse
- EMA: Authorised (2014) as Scenesse
- Health Canada: Not approved
- Indication: Erythropoietic protoporphyria
Afamelanotide is available in the US and EU but has a narrow, orphan-drug label restricted to EPP.
Triptorelin
- FDA: Approved (multiple formulations and indications including prostate cancer, endometriosis, CPP)
- EMA: Not authorised in the European Union
- Health Canada: Approved
- Indications: Prostate cancer, endometriosis, central precocious puberty
Triptorelin has broader regulatory coverage (US and Canada) and wider therapeutic indications, reflecting its use in more common diseases.
Who Is Each Compound Best Suited For?
Afamelanotide Is Relevant If You Have:
- Erythropoietic protoporphyria (EPP): This is the only indication afamelanotide is approved for. EPP is a genetic porphyria affecting roughly 1 in 75,000 to 200,000 people. If you have diagnosed EPP and experience photosensitivity despite sun avoidance and protective measures, afamelanotide combined with sun protection is a clinically validated option. Studies show it significantly reduces phototoxic reaction days.
- Interest in tanning without UV exposure (research context): While afamelanotide is not approved for cosmetic tanning, its mechanism is well-understood. Some researchers and biohackers have explored its potential in this domain, though this sits outside licensed medical use.
Triptorelin Is Relevant If You Have:
- Prostate cancer: Triptorelin is a standard first-line treatment for hormone-sensitive prostate cancer, often used alongside anti-androgens to suppress testosterone and slow tumor progression.
- Endometriosis: GnRH agonists like triptorelin are recommended second-line therapy when other treatments fail or are poorly tolerated. They dramatically reduce estrogen and alleviate pain.
- Central precocious puberty: Triptorelin halts early sexual development, allowing more normal growth and development trajectory in children.
- Premenopausal breast cancer: Off-label, some oncologists use GnRH agonists in premenopausal women with hormone-receptor-positive breast cancer.
Safety and Side Effects: A Brief Comparison
Afamelanotide
Common side effects include injection-site reactions (itching, redness) and skin darkening (which is the intended effect but can be cosmetically undesirable to some). Serious adverse events are rare. Because it's delivered via implant and absorbed systemically, monitoring for melanoma risk has been a theoretical concern, though long-term surveillance data in EPP patients do not show an increased melanoma incidence.
Triptorelin
Because it suppresses sex hormones, triptorelin carries more systemic side effects:
- Hot flashes, night sweats (vasomotor symptoms)
- Decreased libido and erectile dysfunction (in men)
- Vaginal dryness (in women)
- Bone density loss (with prolonged use; bone-protective agents are often co-prescribed)
- Injection-site pain
Triptorelin is contraindicated in pregnancy and requires careful baseline monitoring (bone density, cardiac function, PSA in prostate cancer).
Evidence Quality and Trial Data
Both compounds have strong clinical evidence:
- Afamelanotide: 23 registered clinical trials, predominantly in EPP. The pivotal trial was large, randomized, and published in a top-tier journal. Evidence grade: A (high-quality RCT data in narrow population).
- Triptorelin: 40 registered clinical trials across multiple indications. Decades of clinical use with extensive safety and efficacy data in prostate cancer, endometriosis, and CPP. Evidence grade: A (robust RCT data in multiple populations).
Triptorelin has more trial data because it's used for more common conditions and has been in clinical use longer. Both support their respective uses.
The Bottom Line: When to Consider Each
These are not competing therapies—they address entirely different diseases via different mechanisms. Your choice (if you have a choice) depends entirely on your diagnosis:
- Have diagnosed EPP with photosensitivity? → Afamelanotide is a clinically validated option to explore with your dermatologist.
- Have prostate cancer, endometriosis, or CPP? → Triptorelin is an established, evidence-based therapy your oncologist or endocrinologist may recommend.
There's no scenario where you'd choose between them for the same condition, because they're used for different diseases. Understanding the distinction helps clarify why each has earned regulatory approval in its respective domain.
For more on peptide mechanisms and how approved compounds differ from research compounds, explore our glossary.